GlaxoSmithKline ( NYSE: GSK ) is a global pharmaceutical company known for producing a variety of drugs and consumer goods such as AquaFresh toothpaste, Tums gastrointestinal aid, and Amoxil (amoxicillin) antibiotic. The reasons for the drop in share price could be attributed to a couple of events. GSK Q2 2014 results of $9.3 billion revenues, although comparable to the $9.3 billion revenue Q1 2014 results, is a 7% decline from Q2 2013 results of $10.4 billion. A drop in quarterly year over revenues combined with an uncertain climate in Eastern Europe likely contributed to the drop in stock price. GSK is not only affected by the economic climate, but is also affected by other world affairs. GSK is dealing with investigations in China over alleged bribery of doctors by GSK China to prescribe GSK products to patients. The Chinese government has cracked down on this behavior in an effort to reduce corruption within their nation, and the situation has caused some investors to sell shares of GSK.